FDA Clears AI-Powered Wristband for Essential Tremor Relief
The FDA has approved the Felix™ NeuroAI™ Wristband, a wearable AI-driven neurostimulation device, for treating upper limb functional limitations in adults with essential tremor. The cloud-based system delivers personalized therapy, continuously adjusting stimulation throughout the day based on the patient’s needs.
“The Felix wristband represents a significant step forward in noninvasive, personalized treatment options for essential tremor,” said Rajesh Pahwa, M.D., Laverne and Joyce Rider Professor of Neurology at the University of Kansas School of Medicine, Director of the Movement Disorder Program at The University of Kansas Health System. “For many patients, current treatment options fall short-pharmaceutical treatments are helpful for less than 50% of the patients, and deep brain stimulation and focused ultrasound, while effective, require surgical intervention. This new AI wearable wristband backed by clinical evidence is an effective treatment option in patients with essential tremor.”
Essential tremor is the most common type of tremor disorder, affecting approximately 7 million people in the U.S., and is about seven times more common than Parkinson’s disease. It causes involuntary, rhythmic shaking, most often in the hands, which can make simple and everyday activities like drinking from a glass or tying shoelaces difficult. Traditional treatment options are limited, with oral medications providing inconsistent relief and often accompanied by undesirable side effects.4 Surgical interventions such as deep brain stimulation (DBS), while effective, require invasive procedures, carry surgical risks, and may not be suitable or desirable for all patients, particularly older adults or those with coexisting health conditions.
Unlike surgical or pharmacologic interventions, Felix is a noninvasive, wearable device that effortlessly connects to Fasikl’s cloud-based AI platform, enabling continuous brain-AI co-adaptation and personalized therapy. Worn on the wrist, it uses the cloud to dynamically adjust stimulation, offering all-day symptom relief while seamlessly fitting into the wearer’s lifestyle.
The FDA clearance of Felix is supported by compelling data from the TRANQUIL study, a randomized, double-blind, sham-controlled trial that met its primary endpoint. Results showed that the Felix wristband significantly reduced tremors and displayed statistically and clinically significant improvement in the users' ability to perform daily activities compared to those using the sham device (“placebo effect”). Efficacy was consistent across demographics, with no serious device-related adverse events reported. Results were presented as Late-breaking Science at the American Academy of Neurology annual meeting in April 2025, reinforcing Felix’s safety and potential as a first-of-its-kind, noninvasive, AI-powered treatment.
“FDA clearance of Felix marks a defining moment for Fasikl and the millions of people living with essential tremor who have long been underserved by existing therapies,” said Zhi Yang, Ph.D., CEO of Fasikl. “This breakthrough in noninvasive, intelligent, and personalized neuromodulation marks the emergence of AI therapeutics in disease treatment. It offers a new option that is potentially more effective, safer, and more scalable. Our next step is to execute the commercialization plan to support Felix’s initial product launch."
The Felix NeuroAI Wristband will be available by prescription through healthcare providers in select U.S. regions starting in 2025, with nationwide availability expected in 2026.
